GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OSTO:ABLI) » Definitions » Cyclically Adjusted Price-to-FCF

Abliva AB (OSTO:ABLI) Cyclically Adjusted Price-to-FCF : (As of Jun. 11, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Abliva AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Abliva AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Abliva AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB Cyclically Adjusted Price-to-FCF Chart

Abliva AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abliva AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abliva AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Abliva AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abliva AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abliva AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Abliva AB's Cyclically Adjusted Price-to-FCF falls into.



Abliva AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Abliva AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Abliva AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.025/132.2054*132.2054
=-0.025

Current CPI (Mar. 2024) = 132.2054.

Abliva AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.645 100.432 -0.849
201409 -0.443 100.161 -0.585
201412 -0.207 100.225 -0.273
201503 -0.665 99.950 -0.880
201506 -0.730 99.995 -0.965
201509 -0.511 100.228 -0.674
201512 -0.496 100.276 -0.654
201603 -0.447 100.751 -0.587
201606 -0.393 101.019 -0.514
201609 -0.274 101.138 -0.358
201612 -0.339 102.022 -0.439
201703 -0.282 102.022 -0.365
201706 -0.366 102.752 -0.471
201709 -0.283 103.279 -0.362
201712 -0.188 103.793 -0.239
201803 -0.247 103.962 -0.314
201806 -0.429 104.875 -0.541
201809 -0.176 105.679 -0.220
201812 -0.138 105.912 -0.172
201903 -0.108 105.886 -0.135
201906 -0.092 106.742 -0.114
201909 -0.099 107.214 -0.122
201912 -0.110 107.766 -0.135
202003 -0.169 106.563 -0.210
202006 -0.048 107.498 -0.059
202009 -0.048 107.635 -0.059
202012 -0.037 108.296 -0.045
202103 -0.045 108.360 -0.055
202106 -0.075 108.928 -0.091
202109 -0.078 110.338 -0.093
202112 -0.102 112.486 -0.120
202203 -0.056 114.825 -0.064
202206 -0.057 118.384 -0.064
202209 -0.165 122.296 -0.178
202212 -0.007 126.365 -0.007
202303 -0.007 127.042 -0.007
202306 0.004 129.407 0.004
202309 -0.005 130.224 -0.005
202312 -0.001 131.912 -0.001
202403 -0.025 132.205 -0.025

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Abliva AB  (OSTO:ABLI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Abliva AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Abliva AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Abliva AB (OSTO:ABLI) Business Description

Industry
Traded in Other Exchanges
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase.

Abliva AB (OSTO:ABLI) Headlines

No Headlines